FindTrial
Sign In

Sodium pyruvate therapy for the patients with citrin deficiency

Sodium pyruvate therapy for the patients with citrin deficiency - pyruvate therapy for citrin deficiency

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000008528
Enrollment
6
Registered
2012-09-15
Start date
2012-09-15
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

citrin deficiency

Interventions

1) Medicine: sodium pyruvate 2) Duration: 16 weeks, If patient hopes, it can continue. 3) Amount: 100~300 mg/kg/day 4) Number:2~3 times/day after eating orally

Sponsors

Department of Pediatrics, Kobe university Graduate School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) the patients with CTLN2 2) the patients with symptoms of easy fatiqability growth retardation and hypoglycemia in compensation period. 3) the patients with severe hepatic damage by NICCD. 4) the patients with informed concecnt by document was proved.

Exclusion criteria

Exclusion criteria: pregnant woman

Design outcomes

Primary

MeasureTime frame
Adult onset type II citrullinemia 1) improvement of citrulllinemia and hyperannmonemia 2) improvement of impaired consciousness 3) improvement of QOL Compensation period 1) improvement of citrulllinemia and oxidative stress 2) improvement of QOL 3) improvement of appetite habit Neonatal intrehepatic cholestasis caused by citrin deficincy 1) improvement of cholestasis and citrullinemia 2) catch up of body weight—

Countries

Japan

Contacts

Public ContactHiroyuki AWANO

Kobe University Graduate School of Medicine Department of Pediatrics

awahiro@med.kobe-u.ac.jp078-382-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026